Watch UTHR. Know when insiders buy.
One email the day a filing lands. Free.
UTHR
UNITED THERAPEUTICS Corp
563.49
+9.61 +1.74%
USD · Oct 21, 05:20 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · insiders 25, shorts 56
Insiders, 90 days
−$232.3M
net selling · 0 buys, 570 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $24.2BP/E 20.2DIV YIELD —FCF YIELD 4.52%REV TTM $3.2B +2.5%NET INCOME $1.3B +5.5%NET CASH —52W 415.34 – 596.76NEXT EARNINGS Oct 28 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $783.3M | −1.9% | 87.3% | $330.8M | $333M | +7.6% | 7.27 | $313.6M | $108M | $205.6M | Aug 5 |
| Q1 2026 · Mar 31 | $781.5M | −1.6% | 82.9% | $325.8M | $274.9M | −14.7% | 5.82 | $463.3M | $100.8M | $362.5M | May 6 |
| Q4 2025 · Dec 31derived | $790.2M | +7.4% | 86.9% | $356.7M | $364.3M | +20.9% | 7.69 | $346.2M | $172.9M | $173.3M | Feb 25 |
| Q3 2025 · Sep 30 | $799.5M | +6.8% | 87.4% | $388.5M | $338.7M | +9.6% | 7.16 | $562.1M | $210.5M | $351.6M | Oct 29 |
| Q2 2025 · Jun 30 | $798.6M | +11.7% | 89.0% | $364.5M | $309.5M | +11.3% | 6.41 | $191.7M | $62.2M | $129.5M | Aug 5 |
| Q1 2025 · Mar 31 | $794.4M | +17.2% | 88.4% | $382.8M | $322.2M | +5.1% | 6.63 | $461.2M | $74.9M | $386.3M | May 6 |
| Q4 2024 · Dec 31derived | $735.9M | +19.7% | 89.7% | $357.7M | $301.3M | +38.8% | 6.21 | $341.2M | $86.7M | $254.5M | Feb 25 |
| Q3 2024 · Sep 30 | $748.9M | +22.9% | 88.9% | $343.1M | $309.1M | +15.5% | 6.39 | $377.2M | $76.5M | $300.7M | Oct 29 |
| Q2 2024 · Jun 30 | $714.9M | — | 89.1% | $319.9M | $278.1M | — | 5.85 | $232.2M | $45.1M | $187.1M | Jul 30 |
| Q1 2024 · Mar 31 | $677.7M | — | 89.2% | $356.3M | $306.6M | — | 6.17 | $376.5M | $38.2M | $338.3M | Apr 30 |
| Q4 2023 · Dec 31derived | $614.7M | — | 88.4% | $260.1M | $217.1M | — | 4.33 | $150.7M | $78.7M | $72M | Feb 25 |
| Q3 2023 · Sep 30 | $609.4M | — | 88.5% | $327M | $267.6M | — | 5.38 | $346.2M | $65.7M | $280.5M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.2B | 87.9% | $1.5B | $1.3B | 41.9% | 27.86 | $1.6B | $520.5M | $1B | $1B | — |
| FY2024 · to Dec 31 | $2.9B | 89.2% | $1.4B | $1.2B | 41.5% | 24.64 | $1.3B | $246.5M | $1.1B | $1B | — |
| FY2023 · to Dec 31 | $2.3B | 88.9% | $1.2B | $984.8M | 42.3% | 19.81 | $978M | $230.4M | $747.6M | $0 | — |
| FY2022 · to Dec 31 | $1.9B | 92.2% | $979.7M | $727.3M | 37.6% | 15.00 | $802.5M | $138.8M | $663.7M | $0 | — |
| FY2021 · to Dec 31 | $1.7B | 92.7% | $555.9M | $475.8M | 28.2% | 10.06 | $598.2M | $120.8M | $477.4M | — | — |
| FY2020 · to Dec 31 | $1.5B | 92.7% | $593.6M | $514.8M | 34.7% | 11.54 | $755.7M | $59.3M | $696.4M | — | — |
Every number comes from UNITED THERAPEUTICS Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.